KAF156
CKAF156X2201
Phase 2 small_molecule completed
Quick answer
KAF156 for Malaria is a Phase 2 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Pharmaceuticals
- Indication
- Malaria
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed